---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pharmacokinetics"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pharmacokinetics. Topics: Aqueous humor concentrations: phase Ib glaucoma study, Serum concentrations: phase Ia glaucoma study, Vitreous half-life and aqueous-to-vitreous ratio in nonhuman primates, Single-dose toxicokinetics in nonhuman primates, and 3 further topics. 7 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Aqueous humor concentrations: phase Ib glaucoma study

> “Mean (SD) and median (min, max) ANX007 levels in aqueous humor on day 29 were 911 ng/ml (846) and 631 (225, 2539) ng/ml in the ANX007 2.5 mg dose group and 5345 ng/ml (6351)”
> “Dose-dependent increase in aqueous unbound ANX007 levels 29 days after a single intravitreal dose.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.3-2"></a>

### Serum concentrations: phase Ia glaucoma study

> “The method for the quantitative determination of unbound ANX007 in human serum used an electrochemiluminescence immunoassay with a quantification range of 1.25 ng/ml to 250.0 ng/ml, run at a minimum required dilution of 40-fold.”
> “Serum unbound ANX007 was not detected”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.3-3"></a>

### Vitreous half-life in humans

No evidence found.

<a id="topic-2.1.2.6.3-4"></a>

### Vitreous half-life and aqueous-to-vitreous ratio in nonhuman primates

> “The ANX007 half-life was approximately 3 days in the vitreous humor.”
> “Aqueous and vitreous levels were highly correlated, and aqueous levels of free-ANX007 were approximately four-fold lower than in the vitreous”
> “The half-life of ANX007 in the vitreous following IVT administration was approximately 3 days, which is consistent with published data for other humanized monoclonal antibody fragments administered through this route”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.3-5"></a>

### Single-dose toxicokinetics in nonhuman primates

| Parameter | 1 mg/eye | 5 mg/eye |
| --- | --- | --- |
| Dose volume (µL) | “50” | “100 (two 50 µL doses separated by 10 minutes)” |
| Serum Cmax (ng/mL) | “BQL” | “2.03” |
| Serum AUClast (h*ng/mL) | “BQL” | “204” |
| Serum Tmax (h) | “NA” | “48” |
| Vitreous Cmax (ng/mL) | “468,000” | “2,010,000” |
| Vitreous AUClast (h*ng/mL) | “46,500,000” | “247,000,000” |
| Vitreous Tmax (h) | “6” | “6” |

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.3-6"></a>

### Ocular tissue distribution after repeat dosing in nonhuman primates

> “At day 59 (approximately 4 weeks post-last dose), free-ANX007 persisted in vitreous and aqueous humor but not in the optic nerve, choroid, or retina.”
> “These data indicate that binding of ANX007 to C1q persists to 59 days in all tissues but the optic nerve, and that ANX007 was able to access the back of the eye”
> “Although free-Fab was no longer detected, C1q was still bound to ANX007 and thus fully inhibited in the choroid at day 59 (approximately 4 weeks post-last dose).”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

<a id="topic-2.1.2.6.3-7"></a>

### Immunogenicity: phase I glaucoma studies

> “No ADAs positivity was detected during the study at any ANX007 dose level at any of the timepoints assessed.”
> “Low levels of ADA positivity were detected in 7 patients (1 patient in the sham group, 3 patients in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group).”
> “These patients likely represent false positives in the ADA assay, as there was no change in titer over time and ADA positivity was detected before dosing in the ANX007 groups.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.6.3-8"></a>

### Immunogenicity and systemic exposure in nonhuman primates

> “The generation of anti-drug antibody (ADA) was assessed in a validated assay in the repeat dose 5 mg/eye study, and 9 of the 10 treated animals were ADA positive.”
> “However, the effects of ADA on the toxicokinetics of ANX007 were not included in the toxicokinetic evaluation due to the low and transient systemic exposure of ANX007 in serum”

Source: [Grover et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9907371/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
